biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
17:36 J&J posts results from halted trial of Alzheimer's drug in 523 people✦17:34 Maker of a hair gummy plans a small trial in women with thinning hair✦11:37 A decades-old liver drug joins the world's largest Parkinson's trial✦11:37 China reins in a fast route for gene therapy trials after patient deaths✦05:39 Large trial tests whether a daily pill can slow fast-moving ALS✦05:37 More years of periods and hormone therapy tied to healthier brain vessels✦05:36 Drug-switched brain therapy tried in 3 people with hard-to-treat epilepsy✦23:40 New kind of prostate cancer drug showed promising signs, Yale team reports✦17:36 J&J posts results from halted trial of Alzheimer's drug in 523 people✦17:34 Maker of a hair gummy plans a small trial in women with thinning hair✦11:37 A decades-old liver drug joins the world's largest Parkinson's trial✦11:37 China reins in a fast route for gene therapy trials after patient deaths✦05:39 Large trial tests whether a daily pill can slow fast-moving ALS✦05:37 More years of periods and hormone therapy tied to healthier brain vessels✦05:36 Drug-switched brain therapy tried in 3 people with hard-to-treat epilepsy✦23:40 New kind of prostate cancer drug showed promising signs, Yale team reports
← All story threadsSTORY THREAD

Johnson & Johnson's Alzheimer's drug aimed at tau.

1 report so far. New developments are added to this thread as they happen.

  1. Nov 5, 2026
    RESULTS POSTED FOR HALTED MID-STAGE TRIALControlled trial · 523 people

    J&J posts results from halted trial of Alzheimer's drug in 523 people

    Johnson & Johnson posted results for its halted trial of posdinemab, a drip aimed at tau, a protein that tangles in Alzheimer's brains. Being Patient reported in July it did not slow decline.